Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...

Gilgeous-Alexander led the Thunder with 34 points, seven assists and five rebounds as Oklahoma City improved to 54-12. He also leads the NBA in scoring, averaging 32.8 points per game, which is more ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

London joins a firm whose managing partner, Dena Sharp, was co-counsel with her in the multidistrict litigation against Juul Labs Inc. They met ... committee in the Gilead HIV drug kidney ...